SG11202002753QA - A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia - Google Patents

A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia

Info

Publication number
SG11202002753QA
SG11202002753QA SG11202002753QA SG11202002753QA SG11202002753QA SG 11202002753Q A SG11202002753Q A SG 11202002753QA SG 11202002753Q A SG11202002753Q A SG 11202002753QA SG 11202002753Q A SG11202002753Q A SG 11202002753QA SG 11202002753Q A SG11202002753Q A SG 11202002753QA
Authority
SG
Singapore
Prior art keywords
myeloid leukemia
acute myeloid
new approach
residual disease
minimal residual
Prior art date
Application number
SG11202002753QA
Inventor
Dario Campana
Elaine Coustan-Smith
Original Assignee
Nat Univ Singapore
St Jude Childrens Res Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore, St Jude Childrens Res Hospital Inc filed Critical Nat Univ Singapore
Publication of SG11202002753QA publication Critical patent/SG11202002753QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202002753QA 2017-10-26 2018-10-26 A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia SG11202002753QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577673P 2017-10-26 2017-10-26
PCT/US2018/057753 WO2019084434A1 (en) 2017-10-26 2018-10-26 A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia

Publications (1)

Publication Number Publication Date
SG11202002753QA true SG11202002753QA (en) 2020-05-28

Family

ID=66247055

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002753QA SG11202002753QA (en) 2017-10-26 2018-10-26 A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia

Country Status (3)

Country Link
US (1) US11709164B2 (en)
SG (1) SG11202002753QA (en)
WO (1) WO2019084434A1 (en)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5771722A (en) 1993-11-12 1998-06-30 Kaba High Security Locks Corporation Dual control mode lock system
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
CA2711370C (en) * 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
WO2010110346A1 (en) 2009-03-24 2010-09-30 独立行政法人理化学研究所 Leukemia stem cell markers
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
AU2013299627C1 (en) 2012-08-09 2018-05-31 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CN104583392A (en) 2012-08-22 2015-04-29 耶达研究与发展有限公司 Methods of isolating distinct pancreatic cell types
US20140336942A1 (en) * 2012-12-10 2014-11-13 The Trustees Of Columbia University In The City Of New York Analyzing High Dimensional Single Cell Data Using the T-Distributed Stochastic Neighbor Embedding Algorithm
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
BR112017000301A2 (en) 2014-07-07 2017-11-07 Acetylon Pharmaceuticals Inc treatment of leukemia with histone deacetylase inhibitors
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
JP6930991B2 (en) 2016-02-26 2021-09-01 セルジーン コーポレイション IDH2 inhibitors for the treatment of hematological malignancies and solid tumors

Also Published As

Publication number Publication date
US11709164B2 (en) 2023-07-25
WO2019084434A1 (en) 2019-05-02
US20200340995A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
HK1243900A1 (en) Infrasonic stethoscope for monitoring physiological processes
NO20200625A1 (en) Production monitoring
GB201810300D0 (en) Compounds for new use
GB201709985D0 (en) Tire monitor
ZA202105060B (en) A drug monitoring tool
EP3616177C0 (en) Improved hygiene compliance monitoring
GB201402036D0 (en) Method for determination of the status of a disease
PT3142909T (en) Stress monitoring during the operation of a component
SG11201606307PA (en) A process for the preparation of a feedstock for a hydroprocessing unit
GB2552455B (en) Blood monitoring
GB201814465D0 (en) Monitoring physiological parameters
GB2539632B (en) An apparatus for assisting with the application of a garment
GB201715736D0 (en) Hydrocarbon-emissions monitoring
SG11202002753QA (en) A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia
IL275381A (en) A process for the preparation of crisaborole
GB2563971B (en) Machine monitoring
HK1258181A1 (en) Process for the preparation of a quelating agent
GB202006153D0 (en) Non-invasive elecrticity monitoring
GB2570280B (en) Monitoring apparatus
GB201817806D0 (en) Machine condition monitoring
GB201819486D0 (en) Golf-swing monitoring apparatus
GB201716830D0 (en) New Process
GB201710360D0 (en) Patient monitoring
GB201704130D0 (en) New process for compounds
GB201700873D0 (en) Diagnostic tool